Perbedaan Organon Pharma Indonesia Tbk. dan Wismilak Inti Makmur Tbk.: Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M), sedangkan Wismilak Inti Makmur Tbk. diperdagangkan di Rp1.615 (kapitalisasi pasar 3,32 T, volume 24 jam 1,5 jt). Perbedaan utamanya: Wismilak Inti Makmur Tbk. jauh lebih besar — sekitar 31,8× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| SCPI | WIIM | |
|---|---|---|
Kapitalisasi Pasar | 104,4 M | 3,32 T |
Volume | — | 1,5 jt |
Lot | — | 14,97 rb |
Perputaran | — | 2,37 M |
Harga Rata-rata | — | 1.585,03 |
Nilai Transaksi | — | 2,37 M |
Harga Ekuilibrium Indikatif | — | 1.615 |
Volume Ekuilibrium Indikatif | — | 49 |
Imbal hasil berjalan pada periode standar
Berita terbaru kedua aset
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →PT Wismilak Inti Makmur Tbk (the Company) was established based on Notarial Deed No. 22 of Bagio Atmadja, S.H., dated December 14, 1994.
Selengkapnya di halaman WIIM →